

**Reference:** FOI.ICB-2324/372

**Subject:** Community Dermatology Services

*I can confirm that the ICB does hold the information requested; please see responses below:*

QUESTION			RESPONSE		
Q1. Does the ICB commission Community Dermatology Services?			Yes		
Q2. If yes, please complete the table below:			Name of Dermatology Service provider	Number of patients contracted/ treated in the past year by the Dermatology Service	Address where the Dermatology Services are provided
Name of Dermatology Service provider	Number of patients contracted/ treated in the past year by the Dermatology Service	Address where the Dermatology Services are provided			
1)			Sirona care & health	5247	a) William Budd HC Downton Road, Knowle, Bristol, BS4 1WH
					b) Amelia Nutt HC Queens Road, Bishopsworth, Bristol, BS13 8QB c) Greenway community practice

			<p>Greystoke Avenue, Southmead, Bristol BS10 6AF</p> <p>d) Harbourside Family Practice 2 Haven View, Portishead, BS20 7QA</p> <p>e) Stockwood Medical Centre Hollway Road, Stockwood Bristol, BS14 8PT</p> <p>f) Kingswood Health Centre Alma Road, Kingswood, Bristol, BS15 4EJ</p> <p>g) Cadbury Heath Healthcare Parkwall Road, Cadbury Heath, Bristol, BS30 8HS</p> <p>h) Yate West Gate Centre 21 West Walk, Yate, BS37 4AX</p> <p>i) Southmead Health Centre Ullswater Road, Bristol, BS10 6DF</p>
<p>Q3. Do the Community Dermatology Service providers treat patients with any of the following drug types?</p> <ul style="list-style-type: none"> <li>• Monoclonal antibody drugs (e.g. Adalimumab, Tralokinumab, Dupilumab, Secukinumab, Ustekinumab)</li> <li>• JAK inhibitors (e.g. Abrocitinib, Baricitinib, Upadacitinib)</li> </ul>	<p>No</p>		

<p>Q4. Do the Community Dermatology Service providers initiate treatment with any of the following drug types?</p> <ul style="list-style-type: none"><li>• Monoclonal antibody drugs (e.g. Adalimumab, Tralokinumab, Dupilumab, Secukinumab, Ustekinumab)</li><li>• JAK inhibitors (e.g. Abrocitinib, Baricitinib, Upadacitinib)</li></ul>	<p>No</p>
--	-----------

***The information provided in this response is accurate as of 25 January 2024 and has been approved for release by Sarah Truelove, Deputy Chief Executive and Chief Finance Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.***